Guillermo A. Izquierdo

Doctor Fedriani Avenue 3
Sevilla, AN 41009, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 190 publications

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Journal: CNS drugs

Published: July 17, 2025

Real-World Experience of Sustained-Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue.

Real-World Experience of Sustained-Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue.

Journal: Behavioural neurology

Published: March 12, 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: September 04, 2024

Leptin and Leptin Signaling in Multiple Sclerosis: A Narrative Review.

Leptin and Leptin Signaling in Multiple Sclerosis: A Narrative Review.

Journal: Neuromolecular medicine

Published: June 28, 2024

No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.

No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 21, 2024

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.

Journal: Multiple sclerosis and related disorders

Published: March 01, 2024

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal: Journal of medical economics

Published: December 12, 2023

Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.

Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: September 11, 2023

Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.

Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.

Journal: PLOS digital health

Published: June 29, 2023

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

Journal: JAMA neurology

Published: June 05, 2023

Risk of secondary progressive multiple sclerosis after early worsening of disability.

Risk of secondary progressive multiple sclerosis after early worsening of disability.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: April 27, 2023

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.

Journal: Brain : a journal of neurology

Published: March 01, 2023

Showing 1-12 of 190

Last Updated: 09/26/2026